It has been suggested this lipid-specific antibody response plays an important role in modulating disease activity in the CNS as intrathecal synthesis of lipid-reactive IgM correlates not only with a more aggressive disease course [38], but also a reduced risk of patients developing natalizumab-associated PML [11]. This evidence concerns the gene CD40LG and progressive multifocal leukoencephalopathy.